Becton Dickinson and Co (BDX) Shares Bought by Pennsylvania Trust Co

Pennsylvania Trust Co grew its position in Becton Dickinson and Co (NYSE:BDX) by 9.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,090 shares of the medical instruments supplier’s stock after acquiring an additional 2,153 shares during the quarter. Pennsylvania Trust Co’s holdings in Becton Dickinson and were worth $5,553,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the company. Family Firm Inc. raised its stake in shares of Becton Dickinson and by 0.5% during the second quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock worth $236,000 after purchasing an additional 6 shares during the last quarter. Northwest Quadrant Wealth Management LLC raised its stake in shares of Becton Dickinson and by 0.4% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after purchasing an additional 6 shares during the last quarter. NBT Bank N A NY raised its stake in shares of Becton Dickinson and by 0.3% during the second quarter. NBT Bank N A NY now owns 3,351 shares of the medical instruments supplier’s stock worth $654,000 after purchasing an additional 10 shares during the last quarter. Good Life Advisors LLC raised its stake in shares of Becton Dickinson and by 0.6% during the second quarter. Good Life Advisors LLC now owns 2,494 shares of the medical instruments supplier’s stock worth $491,000 after purchasing an additional 14 shares during the last quarter. Finally, Pathstone Family Office LLC raised its position in Becton Dickinson and by 0.4% in the second quarter. Pathstone Family Office LLC now owns 3,974 shares of the medical instruments supplier’s stock worth $2,530,000 after acquiring an additional 15 shares in the last quarter. Institutional investors and hedge funds own 75.54% of the company’s stock.

Several research firms have issued reports on BDX. Zacks Investment Research cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Evercore ISI began coverage on Becton Dickinson and in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 price objective for the company. Citigroup upgraded Becton Dickinson and from a “sell” rating to a “neutral” rating in a research report on Friday, January 5th. KeyCorp began coverage on Becton Dickinson and in a research report on Friday, January 5th. They issued an “overweight” rating and a $260.00 price objective for the company. Finally, Deutsche Bank set a $260.00 price objective on Becton Dickinson and and gave the stock a “buy” rating in a research report on Friday, December 29th. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and has an average rating of “Buy” and a consensus price target of $230.20.

Becton Dickinson and Co (NYSE BDX) opened at $228.54 on Wednesday. Becton Dickinson and Co has a 52-week low of $169.19 and a 52-week high of $230.12. The firm has a market capitalization of $60,665.43, a price-to-earnings ratio of 49.15, a PEG ratio of 1.78 and a beta of 1.07. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter last year, the business posted $2.12 earnings per share. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. sell-side analysts forecast that Becton Dickinson and Co will post 10.66 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 8th were given a $0.75 dividend. The ex-dividend date was Thursday, December 7th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.31%. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.73. Becton Dickinson and’s dividend payout ratio (DPR) is currently 64.52%.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Week Herald and is owned by of Week Herald. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://weekherald.com/2018/01/17/becton-dickinson-and-co-bdx-shares-bought-by-pennsylvania-trust-co.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply